cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Celldex Therapeutics Inc
8 own
24 watching
Current Price
$37.02
$-0.75
(-1.99%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
0
52-Week High
52-Week High
53.18000
52-Week Low
52-Week Low
22.11000
Average Volume
Average Volume
0.35M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization0
icon52-Week High53.18000
icon52-Week Low22.11000
iconAverage Volume0.35M
iconDividend Yield--
iconP/E Ratio--
What does the Celldex Therapeutics Inc do?
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers. In addition, the company focuses on the discovery and development of antibody-based drugs targeting receptor tyrosine kinases, such as CDX-0158, a humanized monoclonal antibody currently in a Phase 1 dose escalation study in refractory gastrointestinal stromal tumors and other KIT positive tumors; and CDX-3379, a human monoclonal antibody, which has completed a Phase 1b study in patients with solid tumors. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. The company is headquartered in Hampton, New Jersey.
Read More
How much money does Celldex Therapeutics Inc make?
News & Events about Celldex Therapeutics Inc.
Globe Newswire
10 months ago
- Data updates at EAACI 2023 continue to position barzolvolimab as a potential best-in-class addition to a historically limited treatment landscape -- At week 24, 55% of all patients with CSU in the 1.5 mg/kg, 3.0 mg/kg and 4.5 mg/kg dose groups had complete response (UAS7) and 69% had well-...
Globe Newswire
1 year ago
HAMPTON, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30th at 11:30 am ET. A webcast of the ...
Globe Newswire
1 year ago
- Rapid, profound and durable responses across multiple dosing groups with favorable safety profile observedpositioning barzolimab as a potential best-in-class addition to a historically limited treatment landscape -- At week 12, 56% of all patients in the 1.5 mg/kg, 3.0 mg/kg and 4.5 mg/kg dose ...
Globe Newswire
1 year ago
Company to host webcast on Sunday, February 26 at 4:00 pm CT/5:00 pm ETHAMPTON, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that data from the Companys Phase 1b multi-dose study of barzolvolimab in chronic spontaneous urticaria will be presented ...
Frequently Asked Questions
Frequently Asked Questions
What is Celldex Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Celldex Therapeutics Inc shares?
plus_minus_icon
How can I buy Celldex Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Celldex Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Celldex Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Celldex Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Celldex Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Celldex Therapeutics Inc?
plus_minus_icon
What percentage is Celldex Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Celldex Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$37.02
$-0.75
(-1.99%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Kura Oncology Inc
Kura Oncology Inc
$18.75
$0.02 (0.11 %)
Mesoblast
Mesoblast
$6.22
$0.22 (3.67 %)
Anavex Life Sciences Corp.
Anavex Life Sciences Corp.
$3.41
$-0.27 (-7.34 %)
Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc.
$1.36
$-0.11 (-7.48 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Kura Oncology Inc
Kura Oncology Inc
$18.75
$0.02 (0.11 %)
Mesoblast
Mesoblast
$6.22
$0.22 (3.67 %)
Anavex Life Sciences Corp.
Anavex Life Sciences Corp.
$3.41
$-0.27 (-7.34 %)
Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc.
$1.36
$-0.11 (-7.48 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00